2013-08-05 18:53:37 - TK: new data presented at ASCO 2013 show that the TK therapy enabled the execution of haploidentical donor transplants, with an overall survival similar to transplants from fully compatible donors
NGR-hTNF: presented at ASCO 2013 final data from a randomised Phase II study indicating a 50% reduction in the risk of death in first-line treatment of squamous lung cancer
Approval of balance sheet and income statement at 30 June 2013 pursuant to Art. 2446 of Italian Civil Code
Call for an ordinary and extraordinary Shareholders’ Meeting on 23 September 2013
Appointment of an independent, non-executive member of the Board and of the manager responsible for preparing the Company’s financial reports
The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Professor Claudio Bordignon, today reviewed and approved the half-year financial report at 30 June 2013.
Claudio Bordignon, Chairman of the Board and CEO of MolMed, commented: “The first half-year of 2013 was characterized by important
confirmations on the potential of both our investigational antitumoral therapeutics: TK and NGR-hTNF. As far as the former is concerned, the large amount of experimental data collected in the past eight years demonstrates the strong contribution that TK can give to the treatment of high-risk leukaemia through bone marrow transplantation from partially compatible donors. As far as NGRhTNF is concerned, in this semester we obtained first results from randomized clinical trials, which have confirmed the previously observed efficacy of NGR-hTNF in various cancer indications. Of particular relevance are the results of a randomized Phase II trial in lung cancer with squamous histology: a 50% decrease in the risk of death was observed in patients treated with NGR-hTNF, thus prioritizing this tumour type as the next candidate for late-stage clinical development. These data coupled with the completion of patient enrolment in our on-going Phase III pivotal trial in malignant pleural mesothelioma, and the very favourable safety profile, could position NGR-hTNF as a potential blockbuster.
I would also like to underline the publication on July 11th in one of the most internationally renowned scientific journals - Science – of results obtained by the Telethon Foundation on two of the gene therapies for which MolMed is involved in the development and manufacturing of viral vectors and transduction of patients hematopoietic stem cell
This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.
MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed’s pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company’s shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)